<DOC>
	<DOCNO>NCT00002678</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective treat patient multiple myeloma . PURPOSE : Randomized phase III trial compare effectiveness various combination chemotherapy regimens treat patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient previously untreated stage I-III multiple myelome treat melphalan combine dexamethasone prednisone induction therapy . - Compare overall survival patient stable respond disease induction treat dexamethasone v observation alone maintenance therapy . - Compare time progression , response rate , quality life patient treat regimen . - Compare toxic effect regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify center , stage ( I II v III ) , creatinine ( le 2.0 mg/dL v 2.0 mg/dL great ) , intention use prophylactic bisphosphonate ( yes v ) . - Induction : Patients randomize 1 4 treatment arm . - Arms I II : Patients receive induction comprise oral prednisone follow oral melphalan day 1-4 . - Arms III IV : Patients receive induction comprise oral melphalan oral dexamethasone ( DM ) day 1-4 course DM day 15-18 course 1-3 . Induction arm I-IV continue every 4 week 12 course absence disease progression unacceptable toxicity . Patients stable respond disease induction proceed maintenance therapy . - Maintenance : - Arms I III : Patients undergo observation . - Arms II IV : Patients receive oral DM day 1-4 . Maintenance therapy continue every 4 week arm II IV every 3 month arm I III absence disease progression unacceptable toxicity . Patients arm I-IV develop disease progression proceed reinduction . - Reinduction : Patients restart induction arm originally randomize . Reinduction continue every 4 week absence stable response last 16 week , disease progression , unacceptable toxicity . Patients achieve stable response last 16 week restart maintenance therapy . Patients experience disease progression reinduction take study . Quality life assess baseline , day 1 course 1-3 every 3 course induction , every 3 month maintenance therapy . Patients follow every 6 month . PROJECTED ACCRUAL : A maximum 600 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated stage IIII multiple myeloma Patients stage I disease must symptomatic Must meet least 1 follow condition : Plasma cell osteolytic lesion soft tissue tumor biopsy At least 10 % plasmacytosis bone marrow aspirate and/or biopsy Less 10 % plasma cell bone marrow least 1 bony lesion Detectable serum Mcomponent IgG , IgA , IgD , IgE If light chain disease ( urine Mprotein ) present , urinary excretion light chain ( Bence Jones ) protein must least 1.0 g/24 hour PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 04 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent serious illness Concurrent diabetes allow , discretion treat physician , change insulin requirement manage No prior concurrent malignancy except curatively treat nonmelanomatous skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunizations No concurrent filgrastim ( GCSF ) growth factor prophylaxis Concurrent epoetin alfa anemia allow Chemotherapy : No prior chemotherapy Endocrine therapy : Prior dexamethasone prednisone radiotherapy spinal cord compression allow cumulative dexamethasone dose great 120 mg cumulative prednisone dose great 792 mg Prior concurrent corticosteroid hypercalcemia allow Radiotherapy : See Endocrine therapy Prior focal radiotherapy allow Concurrent focal radiotherapy induction allow Concurrent radiotherapy palliation ( e.g. , painful osteolytic lesion spinal cord compression ) allow Surgery : At least 2 year since prior surgery radiologic endoscopic diagnosis gastric duodenal ulcer Other : At least 2 year since prior medication radiologic endoscopic diagnosis gastric duodenal ulcer Prior concurrent bisphosphonates hypercalcemia allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>